DcR1 ( decoy receptor 1), also known as CD263, TRAILR3, LIT and TRID, is a glycosyl­phosphatidylinositol (GPI)­linked membrane protein of the TNF receptor superfamily (TNFRSF10C).  DcR1 is highly expressed in peripheral blood lymphocytes, spleen, skeletal muscle, placenta, lung and heart. DcR1 is one of 5 receptors for TRAIL (tumor necrosis factor-related apoptosis inducing ligand), also known as Apo2L (Apo-2 ligand) and TNFSF10. TRAIL preferentially induces apoptosis in tumor cell lines, but not in normal cells. In addition to DcR2, DcR3 and OPG, DcR1 is another TNFRSF member that modulates cytotoxic ligands-induced apoptosis. DcR1 binds TRAIL with high affinity. However DcR1 lacks a cytoplasmic death domain and hence is not capable of inducing apoptosis. DcR1 may protect cells against TRAIL mediated apoptosis by competing with DR4/TRAILR1 and DR5/TRAILR2 for binding to the ligand. Expression of DcR1 has been shown to protect cells bearing DR4 and/or DR5 from TRAIL­induced apoptosis. DcR1 is also a p53-regulated DNA damage-inducible gene. DcR1 is detected in many normal tissues but not in most cancer cell lines, which may explain the specific sensitivity of cancer cells to the apoptosis-inducing activity of TRAIL. The soluble DcR1-Fc fusion protein neutralizes the ability of TRAIL to induce apoptosis.

DcR1 ( decoy receptor 1), also known as CD263, TRAILR3, LIT and TRID, is a glycosyl­phosphatidylinositol (GPI)­linked membrane protein of the TNF receptor superfamily (TNFRSF10C).  DcR1 is highly expressed in peripheral blood lymphocytes, spleen, skeletal muscle, placenta, lung and heart. DcR1 is one of 5 receptors for TRAIL (tumor necrosis factor-related apoptosis inducing ligand), also known as Apo2L (Apo-2 ligand) and TNFSF10. TRAIL preferentially induces apoptosis in tumor cell lines, but not in normal cells. In addition to DcR2, DcR3 and OPG, DcR1 is another TNFRSF member that modulates cytotoxic ligands-induced apoptosis. DcR1 binds TRAIL with high affinity. However DcR1 lacks a cytoplasmic death domain and hence is not capable of inducing apoptosis. DcR1 may protect cells against TRAIL mediated apoptosis by competing with DR4/TRAILR1 and DR5/TRAILR2 for binding to the ligand. Expression of DcR1 has been shown to protect cells bearing DR4 and/or DR5 from TRAIL­induced apoptosis. DcR1 is also a p53-regulated DNA damage-inducible gene. DcR1 is detected in many normal tissues but not in most cancer cell lines, which may explain the specific sensitivity of cancer cells to the apoptosis-inducing activity of TRAIL. The soluble DcR1-Fc fusion protein neutralizes the ability of TRAIL to induce apoptosis.

  

Product Details

 

Gene Symbol: DcR1; LIT; TRID; CD263; TRAILR3; TRAIL-R3; DCR1-TNFR; TNFRSF10C

  

NCBI Gene ID: 8794

 

Uniprot Entry: O14798

 

Construct Details: The recombinant human DcR1-Fc fusion is expressed as a 438 amino acid protein consisting of Ala26 - Pro235 region of DcR1 (UniProt accession #O14798) and a C-terminal Fc from human IgG1, which exists as a dimer under non-reducing conditions (see the gel image inserted).  

 

Source: Human cells stably expressing human DcR1-Fc and growing in chemical-defined media with no animal components or antibiotics

 

Deduced Amino Acid Sequence: 

 

        10         20         30         40         50         60 

 

ATTARQEEVP QQTVAPQQQR HSFKGEECPA GSHRSEHTGA CNPCTEGVDY TNASNNEPSC 

 

        70         80         90        100        110        120 

 

FPCTVCKSDQ KHKSSCTMTR DTVCQCKEGT FRNENSPEMC RKCSRCPSGE VQVSNCTSWD 

 

       130        140        150        160        170        180 

 

DIQCVEEFGA NATVETPAAE ETMNTSPGTP APAAEETMNT SPGTPAPAAE ETMTTSPGTP 

 

       190        200        210        220        230        240 

 

APAAEETMTT SPGTPAPAAE ETMITSPGTP STGTHTCPPC PAPELLGGPS VFLFPPKPKD  

 

       250        260        270        280        290        300 

 

TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST YRVVSVLTVL  

 

       310        320        330        340        350        360 

 

HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY TLPPSREEMT KNQVSLTCLV 

 

       370        380        390        400        410        420 

 

KGFYPSDIAV EWESNGQPEN NYKTTPPVLD SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH 

 

       430 

 

EALHNHYTQK SLSLSPGK 

 

M.W.: Calculated molecular mass (kDa): 47.7; Estimated by SDS-PAGE under reducing condition (kDa): 65-75

 

Calculated PI: 5.22

 

Calculated extinction coefficients (M-1 cm-1, at 280nm): 43650

 

Purity: >95% judged by SDS-PAGE under reducing condition (see the gel image above, labeled as "DTT: +")

 

Formulation: Supplied at 0.5 mg/ml in sterile PBS pH7.4 (carrier & preservative free).

 

Endotoxin Level: <0.1 EU per 1 μg of purified recombinant protein determined by the LAL method

 

Biological Activity: Binds to its ligand human TRAIL and inhibits TRAIL-mediated signaling activity including TRAIL­induced cytotoxicity in L-929 mouse fibroblast cells.

 

 

  

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

Restriction: This product is not transferable or re-sellable.  Customer obtain no right to transfer, assign, or sublicense its use rights, or to transfer, resell, package, or otherwise distribute the product, or to use the product for the benefit of any third party or for any commercial purpose.  Customer may only use the product in compliance with applicable local, state and federal laws, regulations and rules.  Customer may not directly or indirectly use the product or allow the transfer, transmission, export or re-export of all or any part of the product in violation of any export control law or regulation of the united states or any other relevant jurisdiction.  Your use of this product constitutes acceptance of the terms of this limited use agreement.  Please refer to our “terms & conditions” for details.  If you are not willing to accept the limitation of this agreement, G&P Biosciences will accept return of the product for a full/partial refund.

 

Storage

 

The product is shipped at 4°C. Upon receipt, centrifuge the product briefly before opening the vial. It is recommended to store small aliquots at the temperature below –20°C for long-term storage and the product is stable for 3 months. The undiluted protein can be stored at 4°C for no more than 2 weeks.

 

 

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

 

 

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

 

References

 

 

1. FEBS Lett. 416:329-334(1997).

2. J. Biol. Chem. 272:25417 (1997). 

3. J. Exp. Med. 186:1165 (1997).

4. Science 277:815 (1997). 

5. Science 277:818 (1997).

6. J. Immunol. 160:3 (1998).

 

 

 

 

Documentation

 

Product datasheet (pdf) can be downloaded here: FCLSF71-PDS.pdf

 

 

 

Additional supporting documents, including COA and MSDS are available upon request.

 

 

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

Restriction: This product is not transferable or re-sellable.  Customer obtain no right to transfer, assign, or sublicense its use rights, or to transfer, resell, package, or otherwise distribute the product, or to use the product for the benefit of any third party or for any commercial purpose.  Customer may only use the product in compliance with applicable local, state and federal laws, regulations and rules.  Customer may not directly or indirectly use the product or allow the transfer, transmission, export or re-export of all or any part of the product in violation of any export control law or regulation of the united states or any other relevant jurisdiction.  Your use of this product constitutes acceptance of the terms of this limited use agreement.  Please refer to our “terms & conditions” for details.  If you are not willing to accept the limitation of this agreement, G&P Biosciences will accept return of the product for a full/partial refund.